PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML

ABSTRACT:

SUBMITTER: Patel A 

PROVIDER: S-EPMC10429830 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature